Eczema Topicals

Created

2024-05-03

Last Modified

Files

1 Download↓
eczema_topical_codes_050324.csv (4.28 MB)
↓

Tags












Abstract

Concept set intended to identify patients who use topical drugs to treat eczema, for the purpose of defining a study cohort of patients with moderate-to-severe atopic disease.

Affiliation(s)

Children's Hospital of Philadelphia

Funder(s)

Provenance

This concept set was developed for the "Effect of Dupilumab on Onset of Type 1 Disease" study (Incidence of Autoimmune Diseases in Children with Atopy Treated with Dupilumab) to define a cohort of patients with moderate-to-severe atopic disease, including patients with use of moderate-to-severe eczema topicals.

Description

This concept set was developed by a data scientist (KH) for a study led by CHOP clinicians Dr. Jonathan Spergel and Dr. Stan Gabryszewski, which investigates dupilumab use and autoimmune diseases in patients with asthma and atopic dermatitis. The codeset was used to identify a cohort of patients with moderate-to-severe atopic disease, including patients who used moderate-to-severe eczema topicals. The codeset is designed for use with the PEDSnet data model and includes a “severity” column indicating the drug severity (mild, moderate or severe) and a “drug” column indicating one of 28 drugs.

Development Code

https://github.com/PEDSnet/dupilumab_t1/blob/main/functions/codeset_generation.R#L548-L1157

Vocabulary

RxNorm , RxNorm Extension

Clinical Subjects

Corticosteroid
Receptor Agonist
Hormone
Steroid

Related Phenotype

Related Person

Related Study

Thumbnail Image
Effect of Dupilumab on Onset of Type 1 Disease
Children's Hospital of Philadelphia
Study to determine whether use of the Type 2 blocker dupilumab in children with atopic dermatitis and asthma is associated with increased frequency of developing Type 1 disease.

Related Concept Set

Related Publications

Creative Commons license

a CC-BY Attribution 4.0 license.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 license.